Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.52 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.52 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.48 |
| ▸ | IDO1 | P14902 | 2/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29687549 | 0.82 | TAAR1 (0.50) | AOC3TAAR1IDO1SLC6A2SLC6A3 | |
| SCHEMBL15082795 | 0.82 | TAAR1 (0.45) | GABRA1GABRB2AOC3TAAR1IDO1 | |
| SCHEMBL3238216 | 0.82 | TAAR1 (0.50) | AOC3TAAR1IDO1SLC6A2SLC6A3 | |
| SCHEMBL8252287 | 0.82 | GABRA1 (0.54) | GABRA1GABRB2AOC3TAAR1IDO1 | |
| SCHEMBL15160739 | 0.82 | TAAR1 (0.45) | AOC3TAAR1IDO1SLC6A2SLC6A3 | |
| SCHEMBL24210550 | 0.82 | TAAR1 (0.45) | AOC3TAAR1IDO1SLC6A2SLC6A3 | |
| SCHEMBL2563200 | 0.82 | TAAR1 (0.50) | AOC3TAAR1IDO1SLC6A2SLC6A3 | |
| SCHEMBL14478267 | 0.82 | TAAR1 (0.50) | AOC3TAAR1IDO1SLC6A2SLC6A3 | |
| SCHEMBL22204358 | 0.82 | TAAR1 (0.45) | AOC3TAAR1IDO1SLC6A2SLC6A3 | |
| SCHEMBL14718937 | 0.82 | TAAR1 (0.45) | GABRA1GABRB2AOC3TAAR1IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 353 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105073742-B | FLAP conditioning agents | 詹森药业有限公司 | 2017-08-08 | — | — | CN | claimed |
| US-12029739-B2 | SHP2 inhibitor and use thereof | KANAPH THERAPEUTICS INC. (KR) | 2024-07-09 | — | — | US | disclosed |
| US-12029739-B2 | SHP2 inhibitor and use thereof | KANAPH THERAPEUTICS INC. (KR) | 2024-07-09 | — | — | US | disclosed |
| US-11912714-B2 | Spiropyrrolidine derived antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912714-B2 | Spiropyrrolidine derived antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11858945-B2 | Alkyne-containing antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11827615-B2 | Nitrogen-containing compound, electronic element and electronic device | SHAANXI LIGHTE OPTOELECTRONICS MATERIAL CO., LTD. (CN) | 2023-11-28 | — | — | US | disclosed |
| US-20230322722-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | NALO THERAPEUTICS (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230322722-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | NALO THERAPEUTICS (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230303562-A1 | PYRAZOLE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2023-09-28 | — | — | US | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| US-20070135467-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| US-20070105890-A1 | Novel condensed imidazole derivative | DAINIPPON SUMITOMO PHARMA CO., LTD | 2007-05-10 | — | — | US | disclosed |
| US-20070087346-A1 | Orthogonal gene switches | CILIBERTO GENNARO | 2007-04-19 | — | — | US | disclosed |
| US-20070082908-A1 | Bicycle pyrazole derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-12 | — | — | US | disclosed |
| US-7179815-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2007-02-20 | — | — | US | disclosed |
| US-20070015797-A1 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | CHENG PETER T | 2007-01-18 | — | — | US | disclosed |
| CN-1014515-B | Process for preparing nonaromatic fluoroallylamine as MAO inhibitor | MERRELL DOW PHARMA (US) | 1991-10-30 | — | — | CN | disclosed |
| CN-86108051-A | NONAROMATIC FLUOROALLYLAMINE MAO INHIBITORS | — | 1987-08-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303562-A1 | PYRAZOLE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF | CYP51A1, CYP4F11, WEE1 | GABRA1 1882/4885GABRB2 2786/4885AOC3 3970/4885 |
| US-20070105890-A1 | Novel condensed imidazole derivative | DPP4, DPP7, DPP3 | GABRA1 4181/4885GABRB2 3549/4885AOC3 2587/4885 |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | GABRA1 4260/4885GABRB2 4164/4885AOC3 3162/4885 |
| US-20070135467-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | GABRA1 4260/4885GABRB2 4164/4885AOC3 3162/4885 |
| US-20230322722-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | MYC, MYCBP, MYCBP2 | GABRA1 4257/4885GABRB2 3935/4885AOC3 4494/4885 |
| US-11827615-B2 | Nitrogen-containing compound, electronic element and electronic device | NOS1, PRMT1, MNS1 | GABRA1 4733/4885GABRB2 4799/4885AOC3 962/4885 |
| US-11912714-B2 | Spiropyrrolidine derived antiviral agents | ACE, ACE2, PKD1 | GABRA1 3746/4885GABRB2 4596/4885AOC3 4484/4885 |
| US-12029739-B2 | SHP2 inhibitor and use thereof | PTPN1, PTPN5, PTPN2 | GABRA1 3503/4885GABRB2 3659/4885AOC3 4732/4885 |
| US-11858945-B2 | Alkyne-containing antiviral agents | ACE, SARS1, ACE2 | GABRA1 3985/4885GABRB2 4557/4885AOC3 2873/4885 |
| US-20070082908-A1 | Bicycle pyrazole derivative | DPP4, DPP7, DPP3 | GABRA1 1707/4885GABRB2 1124/4885AOC3 930/4885 |
| US-20070015797-A1 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | GPR119, LIPC, ACACA | GABRA1 2317/4885GABRB2 1854/4885AOC3 812/4885 |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | GABRA1 2275/4885GABRB2 1306/4885AOC3 434/4885 |
| US-20070087346-A1 | Orthogonal gene switches | TCF12, JUN, TCF7 | GABRA1 3200/4885GABRB2 2345/4885AOC3 2655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.